Aligos Therapeutics (ALGS) EPS (Weighted Average and Diluted) (2021 - 2026)
Aligos Therapeutics (ALGS) reported EPS (Weighted Average and Diluted) of -$2.21 for Q1 2026, down 4.74% on a YoY basis from -$2.32 in Q1 2025, and down 9.95% quarter-over-quarter from -$2.01 in Q4 2025.
Aligos Therapeutics (ALGS) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Aligos Therapeutics has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$2.21 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 4.74% year-over-year to -$2.21; the trailing twelve-month figure through Mar 2026 stood at -$8.79 (up 49.69% YoY), and the FY2025 full-year result was -$2.45, up 88.3% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$2.21, down from -$2.01 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.81 in Q2 2024, with the low at -$13.1 in Q4 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$2.65 across 5 years, with a median of -$1.53 in 2025.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 288.37% in 2024 against a maximum downside of 3458.97% in 2024.
- Aligos Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.51 in 2022, then surged by 176.47% to $0.39 in 2023, then sank by 3458.97% to -$13.1 in 2024, then surged by 84.66% to -$2.01 in 2025, then declined by 9.95% to -$2.21 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$2.21 (Q1 2026), -$2.01 (Q4 2025), and -$3.04 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -2.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.21 |
| Dec 31, 2025 | -2.01 |
| Sep 30, 2025 | -3.04 |
| Jun 30, 2025 | -1.53 |
| Mar 31, 2025 | -2.11 |
| Dec 31, 2024 | -13.10 |
| Sep 30, 2024 | -3.07 |
| Jun 30, 2024 | 0.81 |
| Mar 31, 2024 | -5.58 |
| Dec 31, 2023 | 0.39 |
| Sep 30, 2023 | -10.37 |
| Jun 30, 2023 | -0.43 |
| Mar 31, 2023 | -0.53 |
| Dec 31, 2022 | -0.51 |
| Sep 30, 2022 | -0.44 |
| Jun 30, 2022 | -0.47 |
| Mar 31, 2022 | -0.84 |
| Sep 30, 2021 | -0.78 |